Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review)

Khasaeva M.A.; Gorokhova T.V.; Boĭko A.N.; Gusev E.I.

Khasaeva M.A.

Kubanskiĭ gosudarstvennyĭ meditsinskiĭ universitet Ministerstva zdravookhraneniia i sotsial'nogo razvitiia RF, Krasnodar;
Nauchno-issledovatel'skiĭ institut fiziko-khimicheskoĭ meditsiny Federal'nogo mediko-biologicheskogo agentstva RF, Moskva

Gorokhova T.V.

Dzhenzaĭm, kompaniia gruppy Sanofi

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

Gusev E.I.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

RSCI AuthorID: 91278
Scopus AuthorID: 35599379800
ORCID: 0000-0003-0742-6875

Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review)

Authors:

Khasaeva M.A., Gorokhova T.V., Boĭko A.N., Gusev E.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(2‑2): 87‑92

Read: 3841 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Khasaeva MA, Gorokhova TV, Boĭko AN, Gusev EI. Alemtuzumab is a new drug based on monoclonal antibodies for treatment multiple sclerosis: treatment possibilities and risks (review). S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(2‑2):87‑92. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Low-level laser therapy in multiple sclerosis: justification and optimization methods of application. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):45-56

Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84

An individual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102

Surgical treatment of secondary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209

Quality of life of patients with multiple sclerosis in the Smolensk region. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):36-40

Hormonal contraception methods and multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):24-30

Epidemiology of multiple sclerosis in the city of Novosibirsk. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):119-127

Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68

A clinical case of X-linked adrenoleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107

Abstract:

Recently published results of II and III phase clinical trials of alemtuzumab in relapsing-remitting multiple sclerosis (MS) are reviewed. This drug has an immunosuppressive mechanism of action with an anti-inflammatory effect higher than that of high-dose beta-interferon. Its neuroprotective activity and possible side-effects are discussed.

Keywords:

alemtuzumab

monoclonal antibodies

multiple sclerosis

CD52 antigen.